Eprosartan is not metabolized by CYP enzymes, and is found not to be an inhibitor of CYP, there are no indications that eprosartan has potential for CYP induction.

Angiotensin II receptor antagonist

Eprosartan is used in the treatment of essential hypertension. It is administered orally.

Eprosartan is not metabolized by CYP, but is eliminated by biliary and renal excretion, primarily as unchanged compound. Less than 2 per cent is excreted as a glucuronide (drugbank). Eprosartan has been shown not to inhibit human cytochrome P450 enzymes CYP1A, 2A6, 2C9/8, 2C19, 2D6, 2E and 3A in vitro in concentrations up to 100µM. This concentration is approximately 15- fold higher than the mean maximum plasma concentration after administration of eprosatran 1200 mg a day for 7 days (SPC, Taavitsainen 2000). In an in vivo drug-drug interaction study eprosartan did not alter the plasma concentration of CYP substrates (Blum 1999). It has an elimination half-life of 5-9 hours (SPC).

Uneventful use reported in 1 patient with acute porphyria.